Foghorn Therapeutics (FHTX) Non-Current Debt (2019 - 2021)

Foghorn Therapeutics' Non-Current Debt history runs 3 years deep, the most recent figure standing at $19.9 million for Q3 2021.

• In Q3 2021, Non-Current Debt rose 126.27% year-over-year to $19.9 million; the TTM figure through Sep 2021 stood at $19.9 million (up 126.27% YoY), while the FY2020 annual figure was $19.7 million, up 79.32% from the prior year.
• Non-Current Debt for Q3 2021 stood at $19.9 million, roughly flat from $19.8 million in the prior quarter.
• The five-year high for Non-Current Debt was $19.9 million in Q3 2021, with the low at $8.8 million in Q3 2020.
• The 3-year median for Non-Current Debt is $19.7 million (2020), against an average of $16.5 million.
• The sharpest annual moves came in 2020 and 2021: Non-Current Debt soared 79.32% in 2020, then jumped 126.27% in 2021.
• Foghorn Therapeutics' Non-Current Debt stood at $11.0 million in 2019, then jumped by 79.32% to $19.7 million in 2020, then gained by 1.32% to $19.9 million in 2021.
• Business Quant data shows FHTX's Non-Current Debt at $19.9 million in Q3 2021, $19.8 million in Q2 2021, and $19.7 million in Q1 2021.